Welcome to our dedicated page for Cardio Diagnostics Holdings SEC filings (Ticker: CDIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cardio Diagnostics Holdings, Inc. filings document a Nasdaq-listed medical technology company with common stock under CDIO and redeemable warrants under CDIOW. The company identifies as an emerging growth company and reports formal disclosures tied to its precision cardiovascular medicine business, including clinical data, reimbursement progress, corporate updates, and strategic priorities furnished through Regulation FD materials.
Its SEC record also includes proxy and annual meeting disclosures covering stockholder voting matters, board and governance items, and meeting procedures. Material-event filings provide updates on corporate communications and security-holder actions, while proxy statements describe proposals submitted to holders of the company’s common stock.
Cardio Diagnostics Holdings, Inc. reported a first-quarter 2026 net loss of $1,788,158 on very early-stage revenue of $2,680, reflecting continued investment ahead of broad commercialization. Operating expenses were $1,787,517, driven mainly by general and administrative costs, sales and marketing, and research and development.
Cash increased to $7,077,021 as of March 31, 2026, helped by $3,693,470 in net proceeds from at-the-market common stock sales, leaving stockholders’ equity at $8,903,399. The company continues to expand adoption of its AI-driven cardiovascular tests, build evidence, and rely on equity financing while acknowledging its disclosure controls were not effective.
Cardio Diagnostics Holdings, Inc. director Peter K. Fung received a grant of stock options for 3,205 shares of Common Stock at an exercise price of $1.95 per share on March 31, 2026. Following the grant, he holds stock options for a total of 9,513 shares, expiring on March 31, 2036.
Cardio Diagnostics Holdings, Inc. director Wendy J. Betts received a grant of stock options covering 3,205 shares of Common Stock. The options have an exercise price of $1.95 per share and expire on March 31, 2036. Following this award, she directly holds 9,513 stock options.
Intrater James reported acquisition or exercise transactions in this Form 4 filing.
Cardio Diagnostics Holdings director James Intrater received a grant of 3,205 stock options on Common Stock at $1.95 per share. These options were granted on March 31, 2026 and expire on March 31, 2036. Following the award, he holds 10,464 stock options directly.
Cardio Diagnostics Holdings director Burton Paul Frederick received a grant of stock options as compensation. He was awarded 3,205 options to buy Common Stock at an exercise price of $1.95 per share, expiring on March 31, 2036. Following this grant, he holds 10,464 derivative securities directly.
Cardio Diagnostics Holdings, Inc. provides AI-driven, epigenetics-based blood tests and software to assess risk and detect coronary heart disease and other cardiovascular conditions. The company reports using a 1-for-30 reverse stock split effective May 12, 2025 and 2,959,469 common shares outstanding as of March 13, 2026.
Cardio details two core tests, Epi+Gen CHD™ for three-year coronary heart disease event risk and PrecisionCHD™ for disease detection, each with a CMS gapfill rate of $854 and supported by peer-reviewed data. It also highlights its HeartRisk™ analytics platform, CLIA-certified lab status, extensive patent portfolio, and a multi-channel go-to-market strategy across health systems, providers, employers, and international partners.
The filing notes an at-the-market Sales Agreement with Craig-Hallum under which Cardio sold 825,268 shares for $11.55 million in 2024 and 292,495 shares for $3.90 million in 2025, plus additional shares after year-end, to fund ongoing commercialization and pipeline development.
Cardio Diagnostics Holdings is hosting an investor call to review its current status, recent developments, and strategic priorities, supported by an investor presentation. The company focuses on precision cardiovascular medicine using epigenetics and artificial intelligence to prevent and detect heart disease earlier and more accurately.
The presentation highlights two AI-powered blood tests: Epi+Gen CHD, which estimates three-year coronary heart disease risk and has an estimated U.S. market of about $125 billion with 146 million eligible Americans, and PrecisionCHD, a diagnostic aid with an estimated $51 billion U.S. market and 60 million eligible Americans, both tied to a final CMS payment rate of $854 per test. Management emphasizes growing clinical validation, cost-effectiveness studies, and international partnerships, including a recently launched internal CLIA lab that has reduced initial lab cost of goods by roughly 30% and targets test turnaround times of about 7–10 business days.
Cardio Diagnostics Holdings, Inc. director Peter K. Fung reported receiving a grant of stock options. On 12/31/2025, he was awarded options to buy 2,306 shares of common stock at an exercise price of $2.71 per share. After this grant, he beneficially owns a total of 6,308 stock options directly. This filing records the equity compensation awarded to a board member and does not involve any sale of shares.
Cardio Diagnostics Holdings, Inc. director Wendy J. Betts reported a stock option grant. On December 31, 2025, she was awarded 2,306 stock options with a right to buy common stock at an exercise price of $2.71 per share. After this grant, she beneficially owns 6,308 derivative securities in the form of stock options, held with direct ownership.
Cardio Diagnostics Holdings, Inc. director Burton Paul Frederick reported a new stock option award. On 12/31/2025, he was granted 2,306 stock options (right to buy common stock) with a conversion or exercise price of $2.71 per share. After this grant, he beneficially owns 7,259 derivative securities in the form of stock options, held in direct ownership. The filing was made on Form 4 for a single reporting person, reflecting an option grant coded as an acquisition.